Stifel Nicolaus analyst Andreas Heine has maintained their bullish stance on 0QDS stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andreas Heine has given his Buy rating due to a combination of factors that suggest a positive outlook for Evonik. The company has set its EBITDA guidance for FY-25 between €2.0-2.3 billion, with the midpoint aligning closely with consensus expectations. This guidance is supported by anticipated net cost savings, lower energy costs due to favorable hedges, and a positive foreign exchange impact, all of which are expected to boost EBITDA beyond the guidance midpoint.
Despite a weaker Q4 performance attributed to one-time effects, the prospects for FY-25 appear strong. The company has shown a promising start to Q1-25, driven by robust methionine pricing in the Nutrition & Care segment and positive trends in Specialty Additives. Additionally, Smart Materials, which lagged in FY-24, is expected to improve significantly in FY-25. These factors, combined with a solid free cash flow outlook, underpin Heine’s optimistic view on Evonik’s stock.
In another report released today, J.P. Morgan also maintained a Buy rating on the stock with a €25.00 price target.